Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension.
about
Current and future pharmacological therapies for NAFLD/NASH.Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension.T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosisFra2 Overexpression in Mice Leads to Non-allergic Asthma Development in an IL-13 Dependent Manner
P2860
Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Pan-PPAR agonist IVA337 is eff ...... is and pulmonary hypertension.
@en
Pan-PPAR agonist IVA337 is eff ...... is and pulmonary hypertension.
@nl
type
label
Pan-PPAR agonist IVA337 is eff ...... is and pulmonary hypertension.
@en
Pan-PPAR agonist IVA337 is eff ...... is and pulmonary hypertension.
@nl
prefLabel
Pan-PPAR agonist IVA337 is eff ...... is and pulmonary hypertension.
@en
Pan-PPAR agonist IVA337 is eff ...... is and pulmonary hypertension.
@nl
P2093
P50
P1476
Pan-PPAR agonist IVA337 is eff ...... is and pulmonary hypertension.
@en
P2093
Anne Cauvet
Irena Konstantinova
Jean-Louis Junien
Jean-Michel Luccarini
Jerome Avouac
Pierre Broqua
Sonia Pezet
Thomas Guilbert
Yannick Allanore
P304
P356
10.1136/ANNRHEUMDIS-2016-210821
P407
P577
2017-08-11T00:00:00Z